PETER WINOCOUR, MB, ChB, MD, FRCP (London) FRCP (Glasgow)

CONSULTANT PHYSICIAN (WITH AN INTEREST IN DIABETES, ENDOCRINOLOGY AND METABOLIC MEDICINE) TO THE EAST AND NORTH HERTFORDSHIRE NHS TRUST

QUEEN ELIZABETH II HOSPITAL, WELWYN GARDEN CITY,

HERTFORD COUNTY HOSPITAL, HERTFORD,

LISTER HOSPITAL, STEVENAGE

October 2024

GMC 02343181

Telephone contact 01438 288324

CONTENTS

1. Brief details ……. 3
2. Personal Statement-CVQ ACCEA Gold award 4-6
3. Brief CV Update ……. 6-7
4. Present appointment …….. 8
5. Previous appointments …….. 9
6. Academic achievements ……. 10
7. Publications …… 11-20
8. Review articles/Book/Chapters/Editorials …….. 21-22
9. Book …… 23
10. Case reports …… 23-24
11. Commissioned articles …….. 25
12. Letters …… 26
13. Administration and committee work …….. 27
14. Teaching experience ……. 28
15. Recent invited talks …….. 29
16. Membership of societies …….. 29

1. BRIEF DETAILS

NAME: Peter Howard Winocour, MB, ChB, MD, FRCP (London) FRCP (Glasgow)

ADDRESS: 41 Christchurch Crescent
Radlett
Herts WD7 8AQ

DATE OF BIRTH: 2nd December 1956

NATIONALITY: British

MARITAL STATUS: Married

SCHOOL EDUCATION: Primary and secondary education at Hutchesons' Boys Grammar School, Beaton Road, Glasgow.

UNIVERSITY EDUCATION:

Faculty of Medicine, University of Glasgow
Date of Entry: October 1974.
Date of obtaining Degree: July 1979

Prize: Mary Margaret Isabel Ure
Prize in Child Health.

1st Class Certificates of Merit:
- Child Health
- Clinical Biochemistry
- Community Medicine
- Pathology, Bacteriology and Immunology

DEGREES/ACCREDITATION:

M.B.Ch.B.	University of Glasgow - 1979
M.R.C.P.	UK - 1982
M.D.	University of Glasgow - 1989
JCHMT	Accreditation in General (Internal) Medicine/ Endocrinology/Diabetes Mellitus - 1991
CCST	1997
FRCP London	1998
FRCP Glasgow	2011

2. Brief updates to CV

Expert clinical advisor NICE ID3831 appraisal : Icosapentyl with statin therapy. January 2021 + Empagliflozin CKD November 2023

Chair RCP L JSC Diabetes and Endocrinology 2017- 2021

Member RCPL YAA Committee 2015-2019

PACES Examiner 2010-2019

Ex officio Member of ABCD committee-Member of JBDS committee

Quality in Care Awards 2019–Patient Care Pathway – Adults

Invited authors Oxford Textbook of Endocrinology and Diabetes 2021 . Strategies for management of type 2 diabetes. Zac Varghese S , Winocour PH .

2009- Awarded Silver National Clinical Excellence award- renewed 2014. Rescinded on retirement 2017

Elsanousi S, Dimitriadis PA, Patel A, Langroudi B, George S, Zalin B, Mohamed S, Yasin Z, Naraynswamy S, Kaplan F, Filipas E, Alsabbagh S, Joharatnam J, Winocour P, Mochloulis G, Zac-Varghese S. Audit into pre-operative workup, surgery and outcomes for primary hyperparathyroidism. Poster presentation, 44th Annual Scientific Meeting BAETS, October 2024, London (accepted)

3. RECENT ARTICLES 2021-24

Dasgupta I, Zac-Varghese S, Chaudhry K, et al. Current management of chronic kidney disease in type-2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association (ABCD-UKKA) guidelines. Diabet Med. 2024;00:e15450.doi:10.1111/dme.15450

Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease : Association of British Clinical Diabetologists and the Renal Association guideline update 2021. Banerjee D, Winocour P, Chowdhury T, et al on behalf of the Association of British Clinical Diabetologists and the Renal Association. BMC Nephrology 2022 ; 23 : 9 : 1-31

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.Janaka Karalliedde,Peter Winocour,Tahseen A. Chowdhury,Parijat De,Andrew H. Frankel,Rosa M. Montero,Ana Pokrajac,Debasish Banerjee,Indranil Dasgupta,Damian Fogarty,Adnan Sharif,Mona Wahba,Patrick B. Mark,Sagen Zac-Varghese,Dipesh C. Patel,Stephen C. Bain. Diabetic Medicine 2022;https://doi.org/10.1111/dme.14769

Zac-Varghese S, Summerhayes B, Winocour P. Managing type 1 diabetes in frailty. BMJ Case Rep 2022;**15**:e253779.doi:10.1136/bcr-2022-253779

A case series of diabetic ketoacidosis associated with SGLT2 inhibitors. Zac-Varghese S, Mathew S, Go D , Winocour P. Practical Diabates 2023 ; 40 (3): 21-25

Current management of chronic kidney disease in type-2 diabetes – a tiered approach: An overview of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guidelines.DOI: 10.1111/dme.15450

4. INVITED LECTURES 2022-2024

Winocour PH. CardioRenal Metabolic Care. The philosophical view – why we must move away from silo working . UK Kidney week . Edinburgh 2024

Winocour PH. The Da Vinci Clue. Looking forward and looking back . ENH Trust Grand Round 2024

Winocour PH . Limitations and Opportunities in managing T1DM DKD . 6th Joint Meeting of ABCD and UKKA. Birmingham 2023

5. PRESENT APPOINTMENT

Consultant Physician (with an interest in Diabetes, Endocrinology and Metabolic Medicine) to the East & North Herts Health Trust, and Honorary Senior Lecturer University of Hertfordshire + Royal Free Hospital School of Medicine. Appointment April 1993.

SUMMARY OF JOB PLAN

Direct clinical care	**6**
Supporting Professional Activities	**2**
TOTAL PROGRAMMED ACTIVITIES (Pas)	**8**

4 diabetes sessions/week (including young adult, virtual, renal, community clinic) and incorporating fortnightly GP visits and service management session.

0.5 metabolic bone-lipid clinic/week.

0.5 joint adolescent diabetes clinic/week.

1 weekly Direct Patient Administration sessions .

Supporting Professional Activity (including appraiser role) 2 PAs .

Unpaid - Clinical Research , National College and ABCD work 1 PA/ week

6. PREVIOUS APPOINTMENTS

August 1979 - February 1980	House Physician Southern General Hospital, Glasgow
February 1980 - July 1980	House Surgeon Western Infirmary/Gartnavel General Hospital, Glasgow
August 1980 - July 1981	Medical Senior House Officer Monklands District General Hospital Airdrie
August 1981 - August 1982	Medical Senior House Officer Ancoats Hospital and North Manchester District General Hospital, Manchester
August 1982 - July 1983	Registrar in General Medicine Infectious Diseases, Diabetes Endocrinology & Renal medicine Stobhill General Hospital, Glasgow
August 1983 - December 1986	Research Fellow in Diabetes University of Manchester Department of Medicine, Hope Hospital, Salford
January 1987 - July 1988	Tutor and Registrar in General Medicine, Diabetes and Endocrinology University of Manchester Department of Medicine, Hope Hospital, Salford
August 1988 - February 1989	Clinical Research Fellow/Honorary Medical Registrar ,University of Manchester Department of Medicine Hope Hospital, Salford and the Royal Infirmary, Manchester
March 1989 - August 1992	Lecturer and Hon Senior Registrar University of Newcastle upon Tyne
September 1992 - March 1993	Lecturer and Hon Senior Registrar , Royal Victoria Infirmary and Uni Dept of Medicine Newcastle upon Tyne

7. ACADEMIC ACHIEVEMENTS

MD THESIS

Studies of metabolic control and complications in insulin dependent diabetes mellitus. (University of Glasgow 1989)

REFEREEING JOURNALS

I regularly review papers on metabolic control and complications of diabetes, diabetic nephropathy, lipids and vascular disease for the British Journal of Diabetes , the British Medical Journal, Diabetic Medicine, Diabetes Care, Diabetologia, BMJ .

8. PUBLICATIONS

ORIGINAL ARTICLES

1. Evaluation of the measurement of blood glucose levels on dried filter paper blood spots.
   WINOCOUR PH, McKINNON GA, McMURRAY JR, ANDERSON DC
   Diabetic Medicine 1985; 2: 269-271.

2. Effect of short term improvements in glycaemic control on serum lipoproteins in insulin-treated diabetics.
   WINOCOUR PH, DURRINGTON PN, HUNT L, ANDERSON DC, COHEN H
   In: Diabetes, Obesity and Hyperlipidaemia
   Eds. CREPALDI G, TIENZO A, BAGGIO G
   Excerpta Medica,International Congress Series 1985;681:269-270

3. Lipoprotein abnormalities in insulin-dependent diabetes mellitus.
   WINOCOUR PH, DURRINGTON PN, ISHOLA M, ANDERSON DC
   Lancet 1986; i: 1176-1178.

4. The relationship between autonomic neuropathy and urinary sodium and albumin excretion in insulin-treated diabetics.
   WINOCOUR PH, DHAR H, ANDERSON DC
   Diabetic Medicine 1986; 3: 436-440.

5. Precise measurement of glycated serum albumin by column affinity chromatography and immunoturbidimetry. READ P, BHATNAGAR D, DHAR H, WINOCOUR PH
   Clinica Chimica Acta 1986; 161: 191-199.

6. Does the measurement of serum fructosamine accurately reflect levels of glycated albumin in insulin-dependent diabetes?
   WINOCOUR PH, BHATNAGAR D, READ P, DHAR H
   Annals of Clinical Biochemistry 1987; 24: 47-52.

7. Glycaemic control and exercise tolerance in hypertensive insulin-treated diabetes during Nifedipine therapy.
   WINOCOUR PH, GORDON C, WALDEK S, COHEN H, ANDERSON DC
   British Journal of Clinical Practice 1987; 41: 772-778.

8. Influence of proteinuria on vascular disease, blood pressure and lipoproteins in insulin- dependent diabetes mellitus.
   WINOCOUR PH, DURRINGTON PN, ISHOLA M, ANDERSON DC, COHEN H
   British Medical Journal 1987; 294: 1648-1651.

9. Hand skin blood flow in insulin-dependent diabetes mellitus.
   WINOCOUR PH, MITCHELL WS, GUSH RJ, TAYLOR LJ, BAKER RD
   Diabetic Medicine 1988; 5: 861-866.

10. Leukocyte microbicidal activity assessed by chemilumines-cence in elderly non-insulin dependent diabetes mellitus.
    WINOCOUR PH, LENTON J, PUXTY JAH, ANDERSON DC
    Diabetes Research 1989; 9: 73-75.

11. Apolipoprotein E polymorphism and lipoproteins in insulin- treated diabetes mellitus.
    WINOCOUR PH, TETLOW L, DURRINGTON PNB, ISHOLA M, HILLIER V, ANDERSON DC
    Atherosclerosis 1989; 75: 167-173.

12. The prevalence of hyperlipidaemia in insulin-dependent diabetes mellitus.
    WINOCOUR PH, DURRINGTON PN, ISHOLA M, HILLIER V, ANDERSON DC
    Quarterly Journal of Medicine 1989; 70: 265-276.

13. Skin blood flow and limited joint mobility in insulin-dependent diabetes mellitus.
    MITCHELL WS, WINOCOUR PH, GUSH RJ, TAYLOR LJ, BAKER RD, ANDERSON DC, JAYSON MIV
    British Journal of Rheumatology 1989; 28: 195-200.

14. Validation of the Friedewald formula for the measurement of low density lipoprotein cholesterol in insulin-dependent diabetes mellitus.
    WINOCOUR PH, ISHOLA M, DURRINGTON PN
    Clinica Chimica Acta 1989; 179: 79-84.

15. Possible predictive factors for the development of pre-eclampsia in insulin-dependent diabetic pregnancies. WINOCOUR PH, TAYLOR R
    Diabetes Research 1989; 10: 159-164.

16. Does residual insulin secretion (assessed by C-peptide concentration) affect lipid and lipoprotein levels in insulin dependent diabetes mellitus?
    WINOCOUR PH, DURRINGTON PN, ISHOLA M, GORDON C, JEACOCK J, ANDERSON DC.
    Clinical Science 1989; 77: 369-374.

17. Relationships between renin, aldosterone, blood pressure and renal function in non-zotaemic hypertensive insulin-dependent diabetics.
WINOCOUR PH, WALDEK S, BAKER RD
Diabetes Research Clinical Practice 1989; 7: 99-108.

18. A comparison of direct measures of glycaemia and glycated blood proteins in insulin-dependent diabetes mellitus.
WINOCOUR PH, BHATNAGAR D, KALSI P, HILLIER V, ANDERSON DC
Clinical Biochemistry 1989; 22: 457-461.

19. Relative clinical usefulness of glycosylated serum albumin and fructosamine during short-term improvements in glycaemic control in IDDM.
WINOCOUR PH, BHATNAGAR D, KALSI P, HILLIER V, ANDERSON DC
Diabetes Care 1989; 12: 665-672.

20. An analysis of glycosylated blood proteins and blood glucose profiles over one year in patients with type 1 diabetes.
WINOCOUR PH, BHATNAGAR D, KALSI P, HILLIER VF, ANDERSON DC
Diabetic Medicine 1989; 6: 709-716.

21. Placebo controlled trial of the effects of guar gum and Metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.
LALOR BC, BHATNAGAR D, WINOCOUR PH, ISHOLA M, ARROL S, BRADING M, DURRINGTON PN.
Diabetic Medicine 1990; 7: 242-245.

22. The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications.
WINOCOUR PH, JEACOCK J, KALSI P, GORDON C, ANDERSON DC.
Diabetes Research Clinical Practice 1990; 9: 23-35.

23. Platelet and plasma vasoactive amines in type 1 (insulin-dependent) diabetes mellitus.
WINOCOUR PH, KLIMIUK P, GRENNAN A, BAKER RD, WEINKOVE C
Annals of Clinical Biochemistry: 1990; 27: 238-244.

24. A one year prospective study of the effects of endogenous insulin reserve (assessed by C-peptide) on metabolic control following a programme of intensified management in insulin-dependent (type 1) diabetes mellitus.
WINOCOUR PH, DURRINGTON PH, KALSI P, BHATNAGAR D, ISHOLA M, GORDON C, ANDERSON DC
Diabetes, Nutrition and Metabolism 1990; 3: 215-224

25. Lymphocyte transformation in elderly non-insulin dependent diabetics before and after improved glycaemic control.
WINOCOUR PH, LENTON J, PUXTY JAH, ANDERSON DC
British Journal Clinical Practice 1990; 44: 259-263

26. A double-blind placebo controlled study of the effects of Bezafibrate on plasma lipids, lipoprotein and fibrinogen in hyperlipidaemic insulin-dependent diabetes mellitus.

WINOCOUR PH, DURRINGTON PN, BHATNAGAR D, ISHOLA M, ARROL S, LALOR BC, ANDERSON DC
Diabetic Medicine 1990; 7: 736-743

27. A randomised cross-over study of the effects of biosynthetic proinsulin on lipid metabolism in type 2 diabetes.
WINOCOUR PH, MALLIK TH, ISHOLA M, BAKER RD, BHATNAGAR D, DURRINGTON PN, ANDERSON DC
Diabetic Medicine 1991; 8: 22-27.

28. The association of different measures of insulinaemia with vascular risk factors in healthy normoglycaemic normotensive non-obese men and women.
WINOCOUR PH, KALUVYA S, BROWN L, FARRER M, MILLAR JP, NEIL HAW, ALBERTI KGMM
Quarterly Journal of Medicine 1991; 79: 539-560.

29. A psychometric evaluation of adult patients with type 1 (insulin dependent) diabetes mellitus: prevalence of psycho logical dysfunction and relationship to demographic variables, metabolic control and complications.
WINOCOUR PH, MAIN CJ, MEDLICOTT G, ANDERSON DC
Diabetes Research 1990; 14: 171-176.

30. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus.
MACKNESS MI, HARTY D, BHATNAGAR D, WINOCOUR PH, ARROL S, ISHOLA M, DURRINGTON PN
Atherosclerosis 1991; 86: 193-199.

31. Lipid peroxides in non-insulin dependent diabetes with macrovascular disease.
VELAZQUEZ E, WINOCOUR PH, LAKER MF, KESTEVEN P, ALBERTI KGMM
Diabetic Medicine 1991; 8: 752-758.

32. The influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition.
WINOCOUR PH, DURRINGTON PN, BHATNAGAR D, ISHOLA M, MacNESS M, ARROL S.
Atherosclerosis 1991; 89: 49-57.

33. Lipoprotein (a) and microvascular disease in Type 1 diabetes mellitus.
WINOCOUR PH, BHATNAGAR D, ISHOLA M, ARROL S, DURRINGTON PN
Diabetic Medicine 1991; 8: 922-927.

34. A comparison of the lipaemic response to a mixed meal and the intravenous fat tolerance test in normolipidaemic and hyperlipidaemic non-insulin dependent diabetes mellitus (NIDDM)
WINOCOUR PH, MALLIK T, BHATNAGAR D, ISHOLA M, ARROL S, McDOWELL D, WEINCOVE C, DURRINGTON PN, ANDERSON DC
Diabetes, Nutrition and Metabolism 1991; 4: 213-219.

35. The relationship between insulinaemia, body mass index and lipoprotein composition in healthy non-diabetic men and women.
WINOCOUR PH, RAMAIYA K, KALUVYA S, BROWN L, MILLAR JP, FARRER M, NEIL HAW, LAKER MF, ALBERTI KGMM
Arteriosclerosis and Thrombosis 1992; 12: 393-402.

36. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesterylester from high density lipoproteins to low density lipo- proteins.
BHATNAGAR D, DURRINGTON PN, MACKNESS M, ARROL S, WINOCOUR PH PRAIS H.
Atherosclerosis 1992; 92: 49-57.

37. Microalbuminuria and associated cardiovascular risk factors in the community.
WINOCOUR PH, HARLAND J, MILLAR JP, LAKER MF, ALBERTI KGMM
Atherosclerosis 1992; 93: 71-81.

38. The effect of Bezafibrate on the composition of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) in hyperlipidaemia associated with Type 1 diabetes.
WINOCOUR PH, DURRINGTON PN, BHATNAGAR D, ISHOLA M, MACKNESS M, ARROL S, ANDERSON DC
Atherosclerosis 1992; 93: 83-94.

39. Does oral carnitine lower serum triglyceride concentrations in hypertriglyceridaemic subjects with and without non-insulin dependent diabetes mellitus?
SUM CF, WINOCOUR PH, AGIUS L, CATALANO C, LAKER MF, ALBERTI KGMM
Diabetes, Nutrition and Metabolism 1992; 5: 175-181.

40. Abnormalities of VLDL, IDL and IDL characterize insulin dependent diabetes mellitus.
WINOCOUR PH, DURRINGTON PN, BHATNAGAR D, ISHOLA M, ARROL S, MACKNESS M
Arteriosclerosis and Thrombosis 1992; 12: 920-928.

41. Serum insulin and triglyceride levels influence erythrocyte sodium-lithium countertransport activity in normoglycaemic individuals.
WINOCOUR PH, THOMAS TH, BROWN L, LAKER MF, WILKINSON R, ALBERTI KGMM
Clin Chim Acta 1992; 208: 193-203.

42. Erythrocyte sodium lithium countertransport activity and total body insulin mediated glucose disposal in normoalbuminuric normotensive Type 1 (insulin dependent) diabetic patients.
CATALANO C, WINOCOUR PH, THOMAS TH, WALKER M, SUM CF, WILKINSON R, ALBERTI KGMM
Diabetologia 1993; 36: 52-56.

43. A cross-sectional evaluation of vascular risk factors in coronary heart disease associated with Type 1 (insulin dependent) diabetes mellitus.
WINOCOUR PH, DURRINGTON PN, MBEWU A, BHATNAGAR D, ISHOLA M, MACKNESS M, ARROL S
Diabetes Res Clin Pract 1992; 18: 173-184.

44. The effect of posture and acute glycaemic control on the excretion of retinal binding protein in normoalbuminuric Type 1 diabetic patients.
CATALANO C, WINOCOUR PH, GILLESPIE S, GIBB I, ALBERTI KGMM
Clinical Science 1993; 84: 461-467.

45. Increased red cell sodium lithium countertransport, total exchangeable sodium and hormonal control of salt balance in normoalbuminuric Type 1 diabetes.
WINOCOUR PH, CATALANO C, THOMAS TH, WILKINSON R, ALBERTI KGMM
Diabetic Medicine 1993; 10: 825-832.

46. Haemostatic function, insulinaemia and cardiovascular risk factors in normoglycaemic men and women.
WINOCOUR PH, NEIL HAW, FARRER M, KESTEVEN P, LAKER MF, ALBERTI KGMM
Nutrition, Metabolism and Cardiovascular Disease 1993; 3: 65-172.

47. Lipoprotein compositional abnormalities and insulin resistance in Type 2 diabetic patients with mild hyperlipidaemia.
STEWART MW, LAKER MF, DYER RG, GAME F, MITCHESON J, WINOCOUR PH, ALBERTI KGMM
Atherosclerosis and Thrombosis 1993; 13: 1046-1052.

48. Association between impaired glucose tolerance and circulating concentration of Lp (a)lipoprotein in relation to coronary heart disease.
FARRER M,GAME FL,ALBERS CJ, NEIL HAW,WINOCOUR PH, LAKER MF, ADAMS PC, ALBERTI KGMM
British Medical Journal 1993; 307: 832-836.

49. Detection of clustering of cardiovascular risk factors during a single practice-based screening programme
HARLAND JOE, WINOCOUR PH, RAMAIYA K, BROWN L, KALLUVYA S, MILLAR JP, KESTEVEN P, LAKER MF, ALBERTI KGMM
Cardiovascular Risk Factors 1994; 5: 18-27.

50. Simvastatin in non-insulin dependent diabetes mellitus: Effect on serum lipids, lipoproteins and haemostatic measures.
FARRER M, WINOCOUR PH, EVANS K, NEIL HAW, LAKER MF, ALBERTI KGMM
Diabetes Res Clin Pract 1994; 23: 111-119.

51. Coronary heart disease is associated with increased lipoprotein (a) concentrations independent of the size of circulating Apolipoprotein (a) isoforms.
FARRER M, GAME FL, ALBERS CJ, NEIL HAW,WINOCOUR PH, LAKER MF, ADAMS PC, ALBERTI KGMM
Arteriosclerosis and Thrombosis 1994; 14: 1272-1283.

52. Contrasting renal and metabolic effects of alpha and beta adrenergic blockade in mildly hypertensive Type 1 (insulin dependent) diabetic subjects.
WINOCOUR PH, CATALANO C, NEW J, ALBERTI KGMM
Nutrition, Metabolism and Cardiovascular Diseases 1995; 5: 217-224.

53. Measures of tubular function in normoalbuminuric insulin dependent diabetic patients and their relationship with sodium lithium countertransport activity.
CATALANO C, WINOCOUR PH, PARLONGO S, GIBB I, GILLESPIE S, ALBERTI KGMM
Nephron 1996; 73: 613 - 618

54. Body mass index, waist-hip ratio and glucose intolerance in Chinese and European adults in Newcastle-upon-Tyne, UK.
UNWIN N, HARLAND J, WHITE M, BHOPAL R, WINOCOUR PH, STEPHENSON P, WATSON W, TURNER C, ALBERTI KGMM
J Epidem Comm Health 1997; 51: 160-166.

55. Association of British Clinical Diabetologists (ABCD) Survey of Secondary Care Services for Diabetes in the United Kingdom 2000. 1: Methods and major findings.
WINOCOUR PH, AINSWORTH A, WILLIAMS R.
Diabetic Medicine 2002; 19:327-333.

56. Association of British Clinical Diabetologists (ABCD) Survey of Specialist Diabetes Care Services in the UK 2000. 2: Workforce issues, roles and responsibilities of Diabetes Specialist Nurses.
WINOCOUR PH, AINSWORTH A, FORD M.
Diabetic Medicine 2002; 19 (supp 4): 27-31.

57. Association of British Clinical Diabetologists (ABCD) Survey of Specialised Diabetes Care Services in the UK 2000. 3: Podiatry Services and related foot care issues.
WINOCOUR PH, MORGAN J, AINSWORTH A.
Diabetic Medicine 2002; 19 (supp 4): 32-38.

58 Association of British Clinical Diabetologists (ABCD) Survey of Specialist Diabetes Care Services in the UK 2000. 4: Diabetic Services and Nutritional Issues.
WINOCOUR PH, MEARING C, AINSWORTH A, WILLIAMS R.
Diabetic Medicine 2002; 19 (supp 4): 39-43.

59. Effective diabetes care – a need for realistic targets.
WINOCOUR PH
British Medical Journal 2002; 324:1577-80

60. Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with Type II diabetes.
COLHOUN HM, THOMSON MJ, MACKMESS MI, MATON SM, BETTERIDGE DJ, DURRINGTON PN et al.
Diabetic Medicine 2002; 19:201-211

61. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor - 1β mutation gene.
BINGHAM C, ELLARD S, VANT'HOFF WG, SIMMONDS HA, MARINAKI M, BADMAN M, WINOCOUR PH et al.
Kidney Int 2003; 63 : 1645-1651

62. Primary prevention of cardiovascular disease with Atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial.
COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.
Lancet 2004: 364; 688-696.

63. Drug therapy for prevention of cardiovascular disease – should surrogate measures be abandoned?
WINOCOUR PH.
Clinical Medicine 2005; 5:282-286

64. ABCD survey of self-awareness of cardiovascular risk amongst consultant diabetologists in the UK.
WINOCOUR PH.
Prac Diabetes Int 2006;23:53-56

65. ABCD position statement on lipid modifying drug therapy in diabetes.
FEHER MD, WINOCOUR PH, on behalf of the Association of British Clinical Diabetologists (ABCD)
Prac Diabetes Int 2007;24 (9):458-462

66. The conflict between specialist diabetes services and acute – general internal medicine for consultant diabetologists in the United Kingdom in 2006. Findings from the 2006 ABCD - Diabetes UK Survey of specialist diabetes services.
WINOCOUR PH, GOSDEN C, WALTON C, TURNER B, NAGI D, HOLT RIG.
Clin Med 2008, 8: 377-380

67. Association of British Clinical Diabetologists (ABCD) - Diabetes UK Survey of specialist diabetes services in the UK, 2006. The consultant physician perspective.
WINOCOUR PH, GOSDEN C, WALTON C, NAGI D, TURNER B, WILLIAMS DRR, JAMES J, HOLT RIG.
Diabetic Med, 2008, 25:643-650

68. Delivery of diabetes care to children and adolescents in East and North Hertfordshire- auditing against NICE Standards.
WINOCOUR PH, AINSWORTH A, WATTS S, RAFFLES A, KAPLAN F, ANGELO-GIZZI J, COURTMAN S, HYDE S. Submitted, 2009.

69. Diabetic Nephropathy – the hypoxic tubular hypothesis.
SINGH D, WINOCOUR PH, FARRINGTON K.
Nature Clinical Practice Nephrology, 2008; 4: 216-226

70. Eryrthropoietic stress and anaemia in diabetes mellitus.
SINGH D, WINOCOUR PH, FARRINGTON K.
Nature Reviews-Endocrinology and Metabolism ; 2009 : 5: 204-210

71. Diabetes specialist nurses and role evolvement : A survey by Diabetes UK and ABCD of specialist diabetes services 2007.
JAMES J, GOSDEN C, WINOCOUR PH, WALTON C, NAGI D, TURNER B, WILLIAMS R, HOLT RIG.
Diabetic Med 2009 ; 26: 560 -565.

72. A national survey of the current state of screening services for diabetic retinopathy: ABCD-Diabetes UK survey of specialist diabetes services 2006.
NAGI D,GOSDEN C,WALTON C,WINOCOUR PH,TURNER B,WILLIAMS R,JAMES J,HOLT RIG.
Diabetic Med ; 2009; 26: 1301-1305

73. Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial injury in diabetes without persistent microalbuminuria ?
SINGH DK, WINOCOUR P,SUMMERHAYES B,VILJOEN A, SIVAKUMAR G, FARRINGTON K.
Diabetes Res Clin Pract , 2009; 85:258-264

74. Low serum osteoprotogerin levels in normoalbuminuric type 1 diabetes mellitus. SINGH D, WINOCOUR P, SUMMERHAYES B, VILJOEN A, SIVAKUMAR G, FARRINGTON K. Acta Diabetol 2010 ; 47 : Supp 1 : S105-S110

75. ABCD position statement on incretin mimetics and DPP-4 inhibitors-2009.
EDWARDS M, WINOCOUR PH, on behalf of the Association of British Clinical Diabetologists (ABCD).
Pract Diabetes Int 2009 ; 26: 191-194

76. Endothelial cell dysfunction, medial arterial calcification and osteoprotogerin in Diabetes mellitus.
SINGH D, WINOCOUR P , FARRINGTON K.
British J Diabetes Vasc Dis 2010; 10:71-77

77. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.
RYDER RJR, THONG KY, CULL M , MILLS AP, WALTON C , WINOCOUR PH, on behalf of the ABCD nationwide exenatide audit contributors.
Pract Diabetes Int 2010 ; 27: 352-357

78. The fifth UK paediatric diabetes service survey: meeting guidelines and recommendations ?
GOSDEN C, EDGE JA, HOLT RIG, JAMES J, TURNER B, WINOCOUR PH, et al.
Arch Diseases Childhood 2010;95:837-840 .

79. ABCD position statement on haemoglobin A1c for the diagnosis of diabetes.
KILPATRICK E , WINOCOUR PH on behalf of the Association of British Clinical Diabetologists (ABCD)
Pract Diabetes Int 2010; 27 : 306-310

80. Oxidative stress in early diabetic nephropathy: fueling the fire.
SINGH DK, WINOCOUR PH, FARRINGTON K.
Nature Rev Endocrinology 2011;7:176-184.

81. Metformin therapy and assessment for vitamin B12 deficiency:is it necessary ?
Qureshi SA, Ainsworth A, Winocour PH
Pract Diabetes 2011 : 28 (7) :302-304

82. The role of the diabetes inpatient specialist nurse in preventing the admission to hospital of patients with diabetes.
Mahaffey K, Stanisstreet D, Ford M, Chapman L, Summerhayes B, Brown S, George S , Winocour PH.
J Diabetes Nursing 2012 ; 16:57-61

83.. Chasing glucose targets in the management of type 2 diabetes.
Winocour PH. Drugs and Therapeutics Bulletin 2013 ; in press

84.. The foot in type 2 diabetes: Is there a link between vascular calcification and bone mineral density ?
Singh DK, Winocour PH, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K.
Diabetes Res Clin Pract 2011;94:410-416

85. Prevalence and progression or peripheral vascular calcification in type 2 diabetic subjects with preserved kidney function.
Singh D, Winocour PH, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K.
Diabetes Res Clin Practice 2012 ;97 : 158-165

86. Expert Position Statement. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organisation guidance 2011. John WG , on behalf of the UK Department of Health Advisory Committee on Diabetes. Diabetic Med 2012 ; 29 : 1350-1357

87. Patidar A, Singh DK, Winocour PH, Farrington K, Baydoun AR. Human uraemic serum displays calcific potential in vitro that increases with advancing chronic kidney disease. Clin Science 2013;125: 237-245.

88. Care of adolescents and young adults with diabetes .-much more than transitional care – a personal view . Winocour PH . Clinical Medicine 2014 : 14 : 274-278

90 . Joint British Societies' guidelines of Prevention of Cardiovascular Disease. Section on Diabetes . Winocour PH , Sattar , N , Grant P. Heart 2014 ; 100 : Suppl 2 :ii 46-49

91. Wright R , Chapman S, Cheer K , Besser REJ , Steele CA, Sankar S , Dimitri P , Winocour PH , Gleeson H. , on behalf of the young adult and adolescent special interest group Training needs in adolescent and young adult health and transition in UK paediatric and adult higher specialist trainees in endocrinology and diabetes *Br J Diabetes Vasc Dis* 2015;15:159-165.

92. Hammersley MA , Rayman G , Winocour PH , Weston C , Birkhead J , on behalf of the TITAN-ACS steering group . An evaluation of the safety and efficacy of a variable rate intravenous insulin infusion in the management of hyperglycaemia in acute coronary syndrome: experience of the TITAN-ACS. *Br J Diabetes Vasc Dis* 2015;15:173-179

93. Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors Dashora U, Gallagher A , Dhatariya K, Winocour P, Gregory R on behalf of the ABCD Committee . British Journal of Diabetes 2016 ; 16 ¨206-210

94. Management of adults with diabetes on the haemodialysis unit.summary of new guidance from the Joint British Diabetes societies (JBDS) and the Renal Association Frankel A , Kazempour –Ardebili S , Bedi R , Chowdhury TA, De P , El-Sherbini N , Game F , Gray S , Hardy D , James J , Kong M-F , Ramlan G , Southcott E , Winocour P British Journal of Diabetes 2016 ; 16 : 69-77

95. Pioglitazone use and risk of bladder cancer :population based cohort study . Letter . Gallagher A , Winocour PH on behalf of the Association of British Clinical Diabetologists . BMJ 2016 ; 352 : i1541

96. Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA) . Mark PB , Winocour PH , Day C . British journal of Diabetes 2017 ;17:64-72

97. Diabetes confers in vitro calcific potential on serum which associates with *in-vivo* vascular calcification.Patidar A, Singh DK, Thakur S, Winocour P, Farrington K , Baydoun A Clin Science 2017 ; 131:991-1000

98. Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes,nephropathy and/or chronic kidney disease. Summary of recommendations .Dasgupta I , Banerjee D , Chowdhury TA , De P , Wahba M , Bain S , Frankel A , Fogarty D , Pokrajac A , Winocour P . British Journal of Diabetes 2017 ;17: 160-164

99. A new integrated care pathway for ambulance attended severe hypoglycaemia in the East of England : The Eastern Academic Health Science Network (EAHSN) Model . Sampson M , Bailey M, Clark J, Evans M, Fong R, Hall H, Hambling C, Hadley-Brown M, Morrish N, Murphy H, Rayman GA, Vithian K, Winocour P, Harries A. Diabetes Res Clin Pract 2017;133:50-59

100. Managing diabetic kidney disease. Zac-Varghese S and Winocour P. British Medical Bulletin, 2017, 1–12.

101. Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care. Winocour PH. Diabetic Med. , 2018 ; 35, 300–305

102. Community-based pre-pregnancy care programme improves pregnancy preparation in women with pregestational diabetes. Yamamoto JM, Hughes DJF , Evans ML, Karunakaran V , Clark JDA, Morrish NJ, Rayman GA, Winocour PH , Hambling C, Harries AW, Sampson MJ, Murphy HR. Diabetologia 2018 ; ; 61,1528–1537

103. Managing hyperglycaemia in patients with diabetes and diabetic nephropathy–chronic kidney disease Summary of recommendations 2018. Winocour PH , Bain SC, Chowdhury T, De P, Pokrajac A, Fogarty D , Frankel A , Banerjee, Wahba M , Dasgupta Br J Diabetes 2018;18:78-89

104. Diabetes and kidney disease: insult added to injury Winocour PH. Br J Diabetes 2018;18:49-50

105. Diabetes UK Position Statements. Management of adults with diabetes on the haemodialysis unit: summary of guidance from the Joint British Diabetes Societies and the Renal Association Frankel AH, Kazempour-Ardebili S , Bedi R , Chowdhury TA, De P, El-Sherbini N, Game F, Gray S, Hardy D,James J , Kong M-F, Ramlan G, Southcott E and Winocour PH Diabet. Med. 2018 35, 1018–1026

106. ENHIDE telehealth support for 148 disengaged young adults with type 1 diabetes : a pilot study- rational and study design . Winocour PH, Solomon A, Currie A, Hardy D, Moore-Haines K, Renshaw C. Br J Diabetes 2018; 18:154-162

107.Dhatariya K, Winocour P , Raffles A. A survey of the management of 16-18 year olds presenting with diabetic ketoacidosis in the UK : a need for standardisation . Br J Diabetes 2019 ; 19 : 29-33

108. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019).Dashora U, Patel DC, Gregory R, Winocour P, Dhatariya K, Nagi D, on behalf of the ABCD executive committee. Br J Diabetes 2019;19:66-72

109. ENHIDE telehealth primary care support of adults with diabetes and chronic kidney disease: a pilot study – rationale and study design . Winocour PH , Moore-Haines K , Solomon A , Currie A, Hardy D . Br J Diabetes 2019;19:53-62

110. A roadmap to recovery: ABCD recommendations on risk stratification of adult patients with diabetes in the post – Covid-19 era. Choudhary P, Wilmot EM, Owen K, Patel DC, L Mills L, Rayman G, Winocour P, Ayman G, Patel R, Hambling C, and Nagi DK. Diabetic Medicine 2020 ;00:e14462

111.Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit. Crabtree TSJ, Rowles S, Tarpey S, Kennedy A, Chalmers J, Nayar R, Lee A, Darzy K, Winocour P, Lindsay J, Idris I, Thong KY, Sen Gupta P, Puttana A, Kumar P, Ryder REJ. Br J Diabetes 2019:19:118-123 (https://doi.org/10.15277/bjd.2019.227)

112.Holistic review of people with diabetes and chronic kidney disease reveals important multi-morbidity and unmet clinical need – The East and North Hertfordshire (ENHIDE) Diabetes Mellitus (DM) Renal Telehealth Pilot study .Winocour PH, Moore-Haines K,Sullivan K , Currie A, Solomon A, Hardy D . Clin Med 2020;20:2 :133-138(10.7861/clinmed.2019-0418)

113.HbA1c in a primary care cohort with Diabetes and Chronic Kidney Disease: The ENHIDE Diabetes Renal Telehealth Project. Winocour PH, Moore- Haines K, Sullivan K, Currie A, Solomon A, Hardy D. Br J Diabetes 2020: 20:130-137.

114.Testing for kidney disease in type 2 diabetes mellitus: consensus statement and recommendations. Winocour PH, Diggle J, Davies S, Beba H, Brake J, Hicks D, Cockwell P, Main C on behalf of the Diabetic Kidney Disease (DKD) Testing Consensus Committee. Diabetes and Primary Care 2020; 22:5:99-107.

115.The effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit. Crabtree TSJ,Winocour P,Darzy K,Phillips S,Evans A,Rohilla A,Raghavan R,Sennik D,Bickerton A,Idris I,Yadagiri M, Ryder REJ, ABCD Canagliflozin Contributors. Br J Diabetes 2020 ; 20 :113-116

116. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter-2 inhibitors with insulin for treatment of Type 1 diabetes (updated October 2020). Dashora U, Patel DC, Gregory R, Winocour P, Dhatariya K, Rowles S, Macklin A, Rayman G, Nagi D, on behalf of the ABCD executive Committee and supported by Diabetes UK. Joint Publication . Br J Diabetes 2020; 20:155-172 and Diabetic Medicine 2020 : 00:e14458

117. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Chowdhury TA, Wahba M, Mallik R, Peracha J, Patel D, De P, Fogarty D, Frankel A, Karraliede J, Mark P, Montero RM,Pokrajac A, Zac Varghese S, Bain SC, Dasgupta I, Banerjee D, Winocour PH, Sharif A. Diabetic Med 2021 Jan 12;e14523. doi: 10.1111/dme.14523.

118. Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement.Basu A,Patel D , Winocour P , Ryder REJ . Br J Diabetes 2021;21:132-148

119. ABCD position statement on risk stratification of adult patients with diabetes during COVID-19 pandemic. Nagi DK , Wilmot EG , Owen K , Patel DC, Mills L , Rayman G , Winocour P , Ayman G, Patel R , Hambling C , Choudhary P. Br J Diabetes 2021;21:123-131

120. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)
Dashora U,A Patel DC,Gregory R, Winocour P, Dhatariya K,Rowles, Macklin A, Rayman G, Nagi D, Whitehead K, Beba H, De P on behalf of the ABCD executive committee and Diabetes UK. Clinical Medicine 2021 Vol 21, No 3: 1–7

121.ABCD and UKKA Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease .Karralliede J, Winocour P, Chowdhury A, De P, Frankel AH, Montero RM, Pokrajac A, Banerjee D, Dasgupta I, Fogarty D, Sharif A, Wahba M, Mark PB, Zac-Varghese S, Patel DC, Bain SC. Br J Diabetes 2021;21:263-271

122. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease : Association of British Clinical Diabetologists and the Renal Association guideline update 2021. Banerjee D, Winocour P, Chowdhury T, De P, Wahba M, Montero R, Fogarty D, Frankel AH, Karralliedde J , Mark PB, Patel Dc, Pokrajac A, Sharif A, Zac-Varghese S, Bain SC, Dasgupta I on behalf of the Association of British Clinical Diabetologists and the Renal Association. BMC Nephrology 2022 ; 23 : 9 : 1-31

123.Management of hypertension in patients with diabetic kidney disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021 D. Banerjee, P. Winocour, T.A. Chowdhury, P. De, M. Wahba, R.M. Montero, D. Fogarty, A.H. Frankel, G. Goldet, J. Karalliedde, P.B. Mark, D.C. Patel, A. Pokrajac, A. Sharif, S. Zac-Varghese, S. Bain, I. Dasgupta, On behalf of the Association of British Clinical Diabetologists and The UK Kidney Association PII: S2468-0249(22)00004-3 DOI: https://doi.org/10.1016/j.ekir.2022.01.004

123. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Karalliedde J , Winocour P, Chowdhury TA , De P , Frankel H , Montero RM , Pokrajac A , Banerjee D , Dasgupta I , Fogarty D , Sharif A , Wahba M , Mark PB, Zac-Varghese S , Patel DC , Bain SC . Diabetic Medicine. 2021;00:e14769. | 1 of 16 https://doi.org/10.1111/dme.14769

124. Zac-Varghese S, Summerhayes B, Winocour P. Managing type 1 diabetes in frailty. BMJ Case Rep 2022;15:e253779.doi:10.1136/bcr-2022-253779

125. A case series of diabetic ketoacidosis associated with SGLT2 inhibitors. Zac-Varghese S, Mathew S, Go D , Winocour P. Practical Diabates 2023 ; 40 (3): 21-25

126. Fineronone in the management of diabetes kidney disease .ABCD UKKA joint consensus statement . 2024 . Online . Khine MT , De P , Frankel AF , Goldet G , Chowdhury T , Fogarty D , Karalliede J , Mallik R , Patel D , Wahba M, Winocour P , Zac Varghese S , Bain S , Sharif A , Bellary S , Dasgupta I

127. Zac-Varghese S, Mark P, Bain S, Banerjee D, Chowdhury TA, Dasgupta I, et al. Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024. BMC Nephrol. 2024;25(1):216

128. Current management of chronic kidney disease in type-2 diabetes – a tiered approach: An overview of the Joint Association of British Clinical Diabetologists and UK Kidney Association guidelines. Indranil Dasgupta, Sagen Zac-Varghese, Khuram Chaudhry,Kieran McCafferty, Peter Winocour, Tahseen A Chowdhury, Srikanth Bellary, Gabrielle Goldet , Mona Wahba , Parijat De, Andrew H Frankel, Rosa M Montero, Eirini Loudaki, Debasish Banerjee, Ritwika Mallik, Adnan Sharif, Naresh Kanumilli, Nicola Milne, Dipesh C. Patel, Stephen C Bain, Ketan Dhatariya, Janaka Karalliedde. Diabetic Med 2024 :00:e15450.doi:10.1111/dme.15450

8. Reviews/ Book Chapters/Editorials/Commentaries

1. Therapeutic aspects of diabetic hyperlipidaemia
   DURRINGTON PN, WINOCOUR PH
   Postgraduate Medical Journal 1989; 65 (Supp 1): 33-41.

2. Plasma lipids and lipoproteins in diabetes mellitus
LAKER MF, WINOCOUR PH
In: Diabetes Annual V 1990
Eds: ALBERTI KGMM, KRALL LJ
Elsevier Science Publishers 1990; 434-470

3. Drug therapy for diabetic dyslipidaemia: a practical approach
WINOCOUR PH, LAKER MF
Diabetic Medicine 1990; 7: 292-298

4. Hyperinsulinaemia as a vascular risk factor: cause, coincidence or methodological artefact. WINOCOUR PH, ALBERTI KGMM
Cardiovascular Risk Factors 1991; 1: 375-385

5. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen and glycaemic control
DURRINGTON PN, WINOCOUR PH, BHATNAGAR D
J Cardiovasc Pharmacol 1990; 16: (Suppl 9): S30-S34.

6. Detection and management of blood lipid disorders
THE COMMITTEE OF THE BRITISH HYPERLIPIDAEMIA ASSOCIATION
Current Science 1990

7. Plasma lipids and lipoproteins in diabetes mellitus
LAKER MF, WINOCOUR PH
In: Diabetes Annual VI, Eds. Alberti KGMM, Krall LJ,
Elsevier Science Publishers 1991: 431-456.

8. Coronary heart disease in diabetes. Antecedents and associations
WINOCOUR PH
Postgraduate Medical Journal 1991; 67: 917-921.

9. Microalbuminuria. Leading Article.
WINOCOUR PH
British Medical Journal, 1992; 304: 1196-1197.

10. Triglycerides and vascular disease
WINOCOUR PH
Diabetes Reviews 1993; 2: 5-8.

11. Microalbuminuria in essential hypertension
WINOCOUR PH
Treating hypertension 1993; 67: 7-10.

12. Management of hyperlipidaemia
The committee of the British Hyperlipidaemia Association.
Postgraduate Medical Journal 1993; 69: 359-369.

13. Microalbuminuria
WINOCOUR PH
In: Cardiovascular disease: risk factors and intervention.
Radcliffe Medical Press 1993; 223-230.

14. Lipids and the hypertensive patient. Should they really make a difference to management decisions?
In: Lipids: Current Perspectives: Ed BETTERIDGE D J
1996; Martin Dunitz (publishers) 115 - 157.

15. The National Service Framework for diabetes and deficiencies in specialist care –Putting the cart before the horse? WINOCOUR PH, GREENWOOD R. Practical Diabetes 2001; 18: 113 – 114.

16. State of the Nation – Specialist Shortfall. WINOCOUR PH. .Diabetes Update 2001; 16 –17.

17. Effects of treatment of hyperglycaemia and hypertension on cardiovascular outcomes in diabetes. In: Heart Disease and Diabetes, Martin Dunitz; ed Fisher BM. 2003; 121-170

18. Prediction of cardiovascular risk in people with diabetes. Review article. WINOCOUR PH, FISHER BM. Diabetic Medicine 2003; 20: 515-527.

19. Will NICE guidelines on the management of type 2 diabetes improve diabetes care? (LEADER) WINOCOUR PH, SHAW K, GREENWOOD R.
Practical Diabetes 2004: 21:3-6

20. All adults with Type 1 diabetes should not routinely receive statin therapy. Practical Diabetes Int 2005, 22:231-232

21. Dual blockade of the renin angiotensin system in diabetes – rationale and risks Kumar R, Winocour PH,
British Journal of Diabetes and Vascular Diseases 2005: 5: 266-271

22. The role of specialist physicians in the commissioning of clinical services. WINOCOUR PH. Editorial,.Clin Med 2008 ; 8: 48-49

23. NICE guidance on type 2 diabetes: too little , too early ? WINOCOUR PH. Editorial. Pract Diab Int 2008; 25: 1-3

24. The 1st John Wales Memorial lecture 2018 : Delivering better diabetes care – its about time ! . Winocour PH. Br J Diabetes 2018; 18: 175-178

25.Taking confidence from CREDENCE and navigating with SONAR: new evidence for reducing renal failure in diabetes. Winocour PH . Br J Diabetes 2019;19:6-7

26. Supporting people with diabetes during the COVID-19 pandemic without face-to-face appointments. Nagi D , Choudhary P, Wilmot E, Winocour P. Editorial. Br J Diabetes 2020;20:1-4

27. Evidence based prevention and management of Type 2 diabetes. Strategies for management of type 2 diabetes. Sagen Zac-Varghese and Peter Winocour. Oxford Textbook of Endocrinology and Diabetes . Oxford University Press 2021 ; in press

9. BOOK

Microalbuminuria: Epidemiology, Biochemistry and Clinical Practice, Cambridge University Press, 1998. Authors: Winocour, PH, Marshall SM.

10. CASE REPORTS

1. Septic arteritis complicating salmonellosis.
   WINOCOUR PH, WILLIAMS GR, BOYD JF, KENNEDY DH
   British Medical Journal 1983; 287: 972-973.

2. Persistent local insulin allergy in a diabetic with chronic lymphatic leukaemia.
   WINOCOUR PH, HAENEY M
   Postgraduate Medical Journal 1986; 62: 865-868.

3. Faecoptysis as the presenting symptom of colonic carcinoma.
   WINOCOUR PH, WILSON LM, BRECKON K, REEVE RS, MORIARTY KJ
   Journal of the Royal Society of Medicine 1989; 82: 441.

4. Severe lactic acidosis and rhabdomyolysis accompanying convulsions.
   WINOCOUR PH, WAISE A, YOUNG G, MORIARTY K
   Postgraduate Medical Journal 1989; 65: 321-322.

5. Difficulties in the localisation and treatment of insulinomas in type 1 multiple endocrine adenomatosis.
   WINOCOUR PH, MORIARTY KJ, HALES CN, ADAMS J, REEVE R, WYNICK D, ALLISON D, BLOOM SR, ANDERSON DC
   Postgraduate Medical Journal 1992; 68: 196-200.

6. Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma: a case report.
   WINOCOUR PH,MASUD T,CLARK F,COOPER B,LAKER MF, ALBERTI KGMM
   Postgraduate Medical Journal 1992; 68: 371-375.

7. Unusual presentation and course of Cushing's Syndrome due to ectopic ACTH secretion by a bronchial carcinoma.
   WINOCOUR PH, TONG P, WHITE J, EDWARDS A, WHITE A, GIBSON J, CLARK F
   Respiratory Medicine 1993; 87: 149-151.

8. Musculoskeletal manifestations during Simvastatin treatment of familial hypercholesterolaemia.
   McDonough JE, WINOCOUR PH, WALKER DJ
   British Journal Rheumatology 1993; 32: 647-648.

9. Reversable hyporeninaemic hypoaldosteronism and life threatening cardiac dysrhythmias: the interaction of non-steroidal anti-inflammatory drugs and autonomic dysfunction.
   MASUD T, WINOCOUR PH, CLARK F
   Postgraduate Medical Journal 1993; 69: 593-594.

10. Nephrolithiasis and early onset microvascular disease in type 1 diabetes mellitus. WINOCOUR PH, CATALANO C, TAPSON JS. Nephron 1994; 66: 364-365.

11. False diagnosis of a catecholamines-secreting paraganglioma in a patient with hypertension and depression. THOMAS G, WINOCOUR PH
    Hospital Medicine 2000; 61: 576 – 7.

12. Multiple Myeloma with hyperparathyroidism.
    TOH V, WINOCOUR PH. Hospital Medicine 2000: 61: 744.

13. Bilateral lower limb pain and swelling in a young girl with type 1 diabetes mellitus.
    TOH V, WINOCOUR PH. Hospital Medicine 2001;62:783-5.

14. Acute Psychosis after the cure of adrenal Cushings syndrome. A Case Report. KUMAR R, WINOCOUR PH. Submitted, 2007.

15. Osmatic demyelination syndrome. Is there a safe limit for correction of hyponatraemia ? KUMAR R, WINOCOUR PH. Submitted 2007.

11. COMMISSIONED ARTICLES

1. Nutrition and therapeutics. Editorial comment.
   Current Opinion in Lipidology 1994; 5: VII-1 - VII-4.

2. Nutrition. Editorial Comment.
   Current Opinion in Lipidology 1995; 6: V 27

3. Nutrition and Therapeutics. Editorial Comment.
   Current Opinion in Lipidology 1996; 7:V1 - V2.

4. Nutrition and Therapeutics. Editorial Comment.
   Current Opinion in Lipidology 1998; 9: 61 - 62.

5. Nutritian and therapeutics. Editorial comment.
   Current Opinion in Lipidology 1998; 9: 497 – 499.

6. The National Service Framework for diabetes and deficiencies in specialist care – Putting the cart before the horse?
   WINOCOUR PH, GREENWOOD R
   Practical Diabetes 2001; 18: 113 – 114.

7. State of the Nation – Specialist Shortfall (in Diabetes)
WINOCOUR PH, Diabetes Update 2001; 16 – 17.

8. The Association of British Clinical Diabetologists (ABCD) Survey of Secondary Care Services for Diabetes in the United Kingdom 2000. Major implications for the National Service Framework for Diabetes.
WINOCOUR PH, Diabetes Today 2002;

9. Utilisation of minimum databases for effective diabetes care.
WINOCOUR PH
British Journal of Diabetes and Vascular Disease 2001; 1:2:136-140.

10. How flawed is the NHS roadmap for diabetes? WINOCOUR PH, Pulse 2003; 63: 44-49.

11. Coming to terms with the reality. Are International treatment guidelines attainable in clinical practice. Counterpoint. WINOCOUR PH: Int J Clinic Pract 2003; Supp 138:9-15

12. Are targets for diabetes care realistic ? WINOCOUR PH, JR College of Physicians Edin. 2005:35:65

13. The role of the Association of British Clinical Diabetologists . WINOCOUR PH. Editorial . Clin Med 2010; 10: 635-636

14. Ryder REJ , McKnight JA, Blann AD , Dhatariya K , Gregory R , Robinson AM, Rowles S, Sharp PS , Winocour PH ., Walton C , on behalf of the Association of British clinical Diabetologists (ABCD) . ABCD position statement on GLP-1 based therapies and pancreatic damage . Prac Diabetes Int 20013 Also access online at : http://www.diabetologsist-abcd.org.uk

12. LETTERS

1. Lp(a) Lipoprotein and Impaired Glucose Tolerance
   FARRER M M, GAME FL, WINOCOUR PH, LAKER MF, ALBERTI KGMM, ALBERS CS, ADAMS PC, NEIL HAW
   British Medical Journal 1994; 308: 136.

2. Management of Mild Hypertension
   Too little emphasis on metabolic factors.
   WINOCOUR PH
   British Medical Journal 1994; 308: 470.

3. Triglyceride Concentrations and Coronary Heart Disease. Routine Measurement is Justified
   WINOCOUR PH
   British Medical Journal 1994; 309: 668.

4. Cost effective strategies for reducing coronary risk in primary care.
   WINOCOUR PH
   British Medical Journal 1995; 311: 573.

5. Metabolic Effects on Antihypertensive treatment.
   WINOCOUR PH
   British Medical Journal 1997; 314: 223-4.

6. National Service Framework for diabetes leave questions open. GREENWOOD RH, SHAW KM, WINOCOUR PH. British Medical Journal 2003; 326: 881-882

7. Physicians in a Foreign Land.
   GREENWOOD R, SHAW K, WINOCOUR PH
   Clin Med 2003; 3:383-4

8. Access to Dietetic Services in the UK (Letter).
   WINOCOUR PH, SHAW K. GREENWOOD R
   Diabetic Medicine 2004; 21:646

9. UK unprepared for diabetes epidemic.
   Greenwood RG, Shaw VS, Winocour PH.
   The Independent Online edition October 14th 2005

14. Integrated care is best model for diabetes. GREENWOOD R, SHAW K, WINOCOUR P. British Medical Journal 2005:331:134.

11. Diabetes and Endocrinology Specialist Registrars Teaching programmes in the United Kingdom – time to set some quality standards ? Results from the ABCD-YDF survey . Diabetic Med 2011 ;

13. ADMINISTRATION AND COMMITTEE WORK

Chaired scientific sessions at meetings of Diabetes UK , the British Hyperlipidaemia Association, Association of British Clinical Diabetologists, Royal Society of Medicine.

Past Chairman of ABCD and member of ABCD executive board

Chairman of the East & North Herts NHS Trust New Drugs and Formulary Committee 2004-2009 and past member of the Hertfordshire Medicines Management Committee.

Independent Clinical Adviser to the Health Ombudsman.

Expert Witness for the Crime Prosecution Service.

ABCD representative on DoH NSF Diabetic Skills and Competency Stakeholder group, and also the UK National Screening Committee Diabetes for Heart Disease and Stroke (DHDS) Project Advisory group

Member of Department of Health Diabetes Programme Board .

Elected as national representative for Diabetes and Endocrinology on the Royal College of Physicians of London Council 2007-2010

Past Chair RCPL JSC in Diabetes and Endocrinology

14. TEACHING EXPERIENCE

Experience in undergraduate instruction has included formal lectures, tutorial groups, individual tuition or ward training of 3rd, 4th and final year medical students and MRCP candidates.

I examined MRCP candidates during the MRCP teaching course at Hope Hospital, Salford, and 'coached' candidates for the MRCP and the MFOM diplomas in Newcastle and Welwyn Garden City. I regularly give lectures in teaching centres in the UK. I have examined Maltese doctors during the preparatory course for the LRCP organized by the University of Newcastle upon Tyne.

MRCP PACES examiner, 2001-2002, 2004, 2006, 2007, 2010-2012 for the Royal College of Physicians, London.

Previous Educational Supervisor of 3 SpR's in Diabetes & Endocrinology in NW Thames regional training programme.

16. MEMBERSHIP OF SOCIETIES

1. Diabetes UK.
2. Association of British Clinical Diabetologists.
3. Royal College of Physicians of London.